Racecadotril Granulate Composition for Dissolution and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing racecadotril granulates face challenges with low bioavailability due to poor wettability and solubility, particularly when using high-pressure compaction, resulting in undesirable particle size distributions that affect dissolution kinetics.
Innovation Solution
A method involving roller compaction at lower pressures (30-70 bar) with specific ingredient ratios and sieving techniques to achieve a targeted particle size distribution, including less than 1% of particles above 0.85 mm and 65-75% between 0.25-0.85 mm, enhances bioavailability and dissolution kinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If high-pressure slugging compaction is used (150-1,300 bar), then granulate can be obtained with particle size below 90 μm (50 w/w%), but dissolution profile is insufficient (54-93% over 45 minutes)
Solution Approach 1:
The patent changes the compaction pressure parameter from high (150-1,300 bar) to low (30-70 bar), and simultaneously optimizes the particle size distribution parameters to achieve better dissolution. The specific particle size distribution (65-75% at 0.25-0.85 mm, 30-50% at 0.425-0.85 mm, etc.) represents optimized parameters that resolve the contradiction between manufacturing precision and dissolution reliability.
2Quantity of substance
If racecadotril is used with low wettability and solubility, then the active ingredient can be incorporated, but bioavailability is negatively affected
Solution Approach 1:
The patent creates a composite granulate material combining racecadotril (40-50 w/w%) with pregelatinized starch (30-40 w/w%) and lactose monohydrate (15-25 w/w%). This composite approach improves bioavailability by combining the active ingredient with excipients that enhance wettability and solubility, resolving the contradiction between maintaining adequate drug content and improving bioavailability.
3Ease of manufacture
If roller compaction at low pressure (30-70 bar) is used, then coarser particle size distribution is obtained, but dissolution kinetics remain similar to fine particles
Solution Approach 1:
The patent optimizes the particle size distribution parameters to achieve a specific coarse distribution (65-75% at 0.25-0.85 mm, 30-50% at 0.425-0.85 mm) that maintains dissolution kinetics while enabling easier manufacture at lower compaction pressures (30-70 bar vs. 150-1,300 bar). This parameter optimization resolves the contradiction between manufacturing ease and particle size precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces racecadotril granulates with improved bioavailability and dissolution profiles, maintaining similar kinetics despite coarser particle sizes, achieved through controlled compaction and sieving processes.
Implementation Method 1
roller compaction with a compaction strength of 30 - 70 bar
Data Source
AI summary
Described is a pharmaceutical granulate formulation comprising racecadotril as active ingredient, a disintegrant, a hydrophilic excipient, a glidant and a lubricant, wherein the granulate is characterized in that less than 2 w/w% has a diameter of above 0.85 mm, 50 – 85 w//w% has a diameter of 0.25 – 0.85 mm, the remaining having a diameter of below 0.25 mm, as well as a method for the preparation thereof.